Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:03:50 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:AGNPF - ALGERNON PHARMACEUTICALS INC - https://algernonpharmaceuticals.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AGNPF - Qnot subscribed0.036-0.0004-1.14.980.0438  0.0438  0.03560.103  0.03615:59:46Jun 3015 min RT 2¢

Recent Trades - All 8 today
Time ETExPriceChangeVolume
15:59:46Q0.048750.0123512
12:35:50Q0.036-0.0004600
12:35:50Q0.04140.005600
12:35:06Q0.03970.003370
12:35:06Q0.04380.00741,200
09:51:55Q0.0356-0.00081,420
09:51:49Q0.04380.00741,000
09:30:30Q0.0356-0.000812
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-30 17:29U:AGNPFNews ReleaseAlgernon Announces Amended Terms for Private Placement and Closing of the First Tranche totaling $621,000
2025-05-27 07:00U:AGNPFNews ReleaseAlgernon Announces $1M Private Placement
2025-05-22 20:50U:AGNPFNews ReleaseAlgernon Closes NoBrainer Imaging Centers, Inc. Acquisition
2025-05-13 07:00U:AGNPFNews ReleaseAlgernon to Acquire NoBrainer Imaging Centers, Inc. - Plans to Establish Alzheimer's Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology
2025-05-05 07:48U:AGNPFNews ReleaseAlgernon Announces Warrant Extension
2025-04-08 07:00U:AGNPFNews ReleaseAlgernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease
2025-03-06 07:00U:AGNPFNews ReleaseAlgernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing
2025-02-11 07:00U:AGNPFNews ReleaseAlgernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sandor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke Study
2025-02-05 07:00U:AGNPFNews ReleaseAlgernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare's USD $170K Equity Investment
2025-01-06 07:00U:AGNPFNews ReleaseAlgernon Pharmaceuticals Receives Notice of Allowance from USPTO For Repirinast in Kidney Disease Patent
2024-11-04 18:31U:AGNPFNews ReleaseAlgernon Announces Warrant Extension
2024-08-20 07:00U:AGNPFNews ReleaseAlgernon Pharmaceuticals Announces Closing of Private Placement
2024-08-13 07:18U:AGNPFNews ReleaseAlgernon Pharmaceuticals Announces Increase to Private Placement
2024-08-07 17:02U:AGNPFNews ReleaseAlgernon Pharmaceuticals Announces Private Placement
2024-08-02 07:00U:AGNPFNews ReleaseAlgernon Pharmaceuticals Announces Closing of Private Placement
2024-07-31 07:00U:AGNPFNews ReleaseAlgernon Pharmaceuticals Announces Increase to Private Placement